IMPORTANT: Interim Clinical Considerations Updated--Janssen COVID-19 Vaccine No Longer Available In the United States

This message was sent to AIM, FAB, Health Systems, INE, IAP, LHD Health Officers, LHD Medical Directors, MACI, MACI 2, PH Imms Leads, MCIR Region Contacts, COVID-19 Vaccine Providers, and Imms All Staff. I apologize for any duplications

Dear Immunization Partners,

Please share the following information with providers in your jurisdiction.

The Centers for Disease Control and Prevention (CDC) updated the Interim Clinical Considerations on May 12, 2023. Guidance for use of Janssen COVID-19 Vaccine has been removed as the vaccine is no longer available in the United States. All remaining U.S. government stock of Janssen COVID-19 vaccine expired May 7, 2023. Dispose of any remaining Janssen product in accordance with local, state, and federal regulations.

People ages 18 years and older who received 1 dose of Janssen COVID-19 vaccine should be considered to have received a single-dose Janssen primary series. People ages 18 years and older who received the Janssen COVID-19 Vaccine primary series dose are recommended to receive 1 bivalent mRNA vaccine dose (Moderna or Pfizer-BioNTech) at least 2 months after completion of the primary series dose (for people who have not previously received any booster doses), or at least 2 months after the last monovalent booster dose. Please refer to the Interim Clinical Considerations for more information.

As a result of the removal of the Janssen COVID-19 vaccine information from the Interim Clinical Considerations, Appendix D, Vaccine administration errors and deviations, has now been moved to Appendix C.

Thank you for all you do in fighting vaccine preventable diseases.

Your Immunization Education and Outreach Team,
Alyssa, Andrea, Dianne, Heidi, Lisa, and Sarah